INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
The Pomerantz LLP law firm has announced a class action lawsuit against Aquestive Therapeutics, Inc. (AQST) regarding alleged securities fraud or unlawful business practices. The lawsuit follows Aquestive's stock price drop after the FDA identified deficiencies in its New Drug Application for Anaphylm, delaying its approval indefinitely. Investors who purchased Aquestive securities during the Class Period have until May 4, 2026, to seek appointment as Lead Plaintiff.
How this was made

The 30-second read
Why it matters
Legal and regulatory setbacks are likely to exert downward pressure in the near term, but the long-term impact depends on resolution outcomes.
Market read
High relevance due to recent legal action and FDA delays impacting AQST's stock and investor sentiment.
What to watch
Potential positive developments, such as settlement or FDA approval upon addressing deficiencies, could reverse the negative trend.
Background
The lawsuit follows a delay in FDA approval due to deficiencies in AQST's NDA for Anaphylm, leading to a stock price decline.
Ticker impact
High relevance due to legal action and recent stock decline
Potential short-term decline of 5-10%
The lawsuit and FDA issues are factual events with immediate market reactions, supported by the bearish sentiment score (-0.42). Technical indicators are not provided, but the recent stock drop suggests negative momentum.
Market effects
Potential negative impact on biotech and pharmaceutical sectors due to legal and regulatory risks
Limited regional impact; primarily affects US biotech stocks
Minimal global market effect, specific to AQST and related sectors
Counterpoint
The lawsuit may be a temporary setback; if AQST resolves the issues swiftly, the stock could rebound in the medium term.
Key entities
- Law FirmPomerantz LLP
Legal firm initiating class action lawsuit against AQST.
- Biotech CompanyAquestive Therapeutics, Inc.
Company facing legal and regulatory challenges affecting its stock.





